Unfunded Medicines
There are a number of medicines in New Zealand supplied by Roche and other pharmaceutical companies that are not publicly funded by PHARMAC, which means members of the New Zealand public will have to pay for this medication. We have developed cost share programmes to help with the cost of unfunded medicines for New Zealanders that need these lifesaving and life extending medicines. The programmes are designed to help reduce the cost of medicines which are not funded by the Government’s drug-buying agency, PHARMAC.
There are 27 Roche medicines registered for sale in New Zealand, however 8 of those are unfunded. These medicines are Avastin, Erivedge, Kadcyla, NeoRecormon, Tamiflu, Zelboraf, Cotellic and Tecentriq.
The programmes are designed to help reduce the cost of medicines which are not funded by the Government’s drug-buying agency, PHARMAC.
There are a number of places you can go for help and support when deciding whether to opt for an unfunded medicine. Follow this link to find out more about unfunded medicines.
Avastin® (bevacizumab)
Uses: Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancersMore Information
Cotellic
Uses: Treatment of advanced (metastatic) melanomaMore Information
Erivedge® (vismodegib)
Uses: Treatment of advanced (metastatic) basal cell carcinomaMore Information
Kadcyla® (trastuzumab emtansine)
Uses: Treatment of advanced (metastatic) HER2-positive breast cancerMore Information
NeoRecormon® (epoetin beta)
Uses: Treatment of AnaemiaMore Information
Tamiflu® (oseltamivir)
Uses: Treatment of influenzaMore Information
Tecentriq® (atezolizumab)
Uses: Treatment of metastatic lung cancer and second line advanced (metastatic) bladder cancerMore Information
